Compare WHD & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHD | VKTX |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2018 | 2014 |
| Metric | WHD | VKTX |
|---|---|---|
| Price | $58.15 | $32.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $56.33 | ★ $95.86 |
| AVG Volume (30 Days) | 664.8K | ★ 2.1M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 18.99 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,079,051,000.00 | N/A |
| Revenue This Year | $43.92 | N/A |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | $305.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.30 | $22.96 |
| 52 Week High | $64.30 | $43.15 |
| Indicator | WHD | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 56.83 |
| Support Level | $55.80 | $29.32 |
| Resistance Level | $58.53 | $36.56 |
| Average True Range (ATR) | 1.90 | 1.24 |
| MACD | -0.17 | 0.34 |
| Stochastic Oscillator | 38.94 | 93.00 |
Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. It has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.